Comparative Pharmacology
Head-to-head clinical analysis: TRI LO SPRINTEC versus TRI LEGEST 21.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TRI LO SPRINTEC versus TRI LEGEST 21.
TRI LO SPRINTEC vs TRI-LEGEST 21
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Tri-Lo Sprintec is a combination oral contraceptive containing ethinyl estradiol and norgestimate. It inhibits ovulation by suppressing gonadotropin release (FSH and LH) from the pituitary, increases viscosity of cervical mucus, and alters endometrial receptivity.
Combination estrogen-progestin contraceptive; suppresses gonadotropins (FSH, LH), inhibits ovulation, alters cervical mucus and endometrium.
Prevention of pregnancy
Prevention of pregnancyTreatment of moderate acne vulgaris in women aged ≥15 years (as triphasic levonorgestrel/ethinyl estradiol)Off-label: regulation of menstrual disorders, dysmenorrhea
One tablet (0.035 mg ethinyl estradiol + 0.180/0.215/0.250 mg norgestimate) orally once daily for 28-day cycle: active tablets on days 1-21, placebo on days 22-28.
One tablet orally once daily for 21 days, followed by 7 tablet-free days. Each tablet contains norgestimate 0.18 mg/ethinyl estradiol 0.025 mg (days 1-7), norgestimate 0.215 mg/ethinyl estradiol 0.025 mg (days 8-14), norgestimate 0.25 mg/ethinyl estradiol 0.025 mg (days 15-21).
None Documented
None Documented
Ethinyl estradiol: terminal half-life approximately 17 hours. Norelgestromin (active metabolite of norgestimate): terminal half-life approximately 28 hours. Clinical context: Ethinyl estradiol half-life supports once-daily dosing with steady-state reached within 7-14 days; norelgestromin half-life allows for sustained progestogenic effect.
Ethinyl estradiol: 13-27 hours (mean ~17 hours); norgestimate active metabolite (norelgestromin): 22-36 hours (mean ~28 hours). Steady-state achieved within 5-10 days.
Ethinyl estradiol is metabolized primarily via CYP3A4; norgestimate is rapidly metabolized to norelgestromin and subsequently to norgestrel, with further metabolism involving CYP3A4 and other CYP enzymes.
Ethinyl estradiol: primarily via CYP3A4; levonorgestrel: primarily via CYP3A4 and reduction, conjugation. Both undergo enterohepatic recirculation.
Renal (approximately 50-60% as metabolites, with about 20% as unchanged ethinyl estradiol glucuronide and 40% as norgestimate metabolites). Fecal (approximately 30-40% as metabolites).
Renal: approximately 50-60% as metabolites; fecal: approximately 40-50% (ethinyl estradiol and norgestimate metabolites excreted in bile and feces); less than 1% unchanged in urine.
Ethinyl estradiol: approximately 97-98% bound to albumin, 2% free. Norelgestromin: approximately 99% bound to sex hormone-binding globulin (SHBG) and albumin.
Ethinyl estradiol: ~97-98% bound to albumin and sex hormone-binding globulin (SHBG); norelgestromin: ~98% bound to albumin and SHBG.
Ethinyl estradiol: Vd approximately 4-5 L/kg. Norelgestromin: Vd approximately 3-4 L/kg. Clinical meaning: indicates extensive distribution into tissues, not primarily confined to plasma volume.
Ethinyl estradiol: 2-4 L/kg; norelgestromin: 2-4 L/kg. Indicates extensive tissue distribution.
Oral: ethinyl estradiol bioavailability approximately 45% (first-pass effect); norgestimate prodrug converted to norelgestromin with systemic bioavailability of approximately 63%.
Oral: approximately 38-48% for ethinyl estradiol due to first-pass metabolism; norgestimate is a prodrug, rapidly deacetylated to norelgestromin with high presystemic conversion.
No specific dosing adjustment required for renal impairment. Use caution in severe renal impairment due to potential fluid retention.
No dose adjustment required for mild to moderate renal impairment. Use is contraindicated in severe renal impairment (GFR <30 mL/min) due to potential fluid retention and electrolyte disturbances.
Contraindicated in severe hepatic disease or hepatocellular carcinoma. For mild to moderate hepatic impairment (Child-Pugh A or B), use alternative contraception; no established dosing guidelines.
Contraindicated in acute hepatic disease, hepatic adenomas or carcinomas, and Child-Pugh Class B or C cirrhosis (severe hepatic impairment). No dose adjustment recommended for mild hepatic impairment (Child-Pugh Class A) but caution is advised.
Not indicated for use before menarche. Post-menarche: same dosing as adults (one tablet daily). Safety and efficacy established in females of reproductive age.
Approved for use in postmenarchal females. Dose is same as adult: one tablet orally once daily for 21 days, then 7 days off. Not indicated for premenarchal females.
Not indicated for postmenopausal women; no geriatric dosing established.
Not indicated for use in postmenopausal women. No specific geriatric dose adjustments, but elderly women should be evaluated for contraindications such as thromboembolic disease and cardiovascular risk.
Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive use. This risk increases with age and with heavy smoking (≥15 cigarettes per day) and is quite marked in women over 35 years of age. Women who use combination oral contraceptives should be strongly advised not to smoke.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptives. Risk increases with age (especially over 35 years) and with heavy smoking (≥15 cigarettes/day). Women who use combination hormonal contraceptives should be strongly advised not to smoke.
["Increased risk of thromboembolic disorders (e.g., venous thromboembolism, stroke, myocardial infarction)","Cigarette smoking increases risk of serious cardiovascular events","Increased risk of hepatic neoplasia (benign and malignant)","Elevated blood pressure","Gallbladder disease","Carbohydrate and lipid metabolic effects"]
Thromboembolic disorders, cardiovascular disease risk, cerebrovascular events, hypertension, gallbladder disease, hepatic neoplasia, impaired liver function, glucose intolerance, lipid effects, headache, irregular bleeding, depression.
["Known or suspected pregnancy","Current or history of thrombophlebitis or thromboembolic disorders","Cerebrovascular or coronary artery disease","Known or suspected breast cancer or other estrogen-sensitive neoplasia","Undiagnosed abnormal uterine bleeding","Benign or malignant liver tumor or active liver disease","Hypersensitivity to any component","Use of hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir with or without dasabuvir"]
Thrombophlebitis or thromboembolic disorders, cerebrovascular or coronary artery disease, known or suspected breast carcinoma, endometrial carcinoma or other estrogen-dependent neoplasia, undiagnosed abnormal genital bleeding, cholestatic jaundice of pregnancy or jaundice with prior pill use, hepatic adenoma or carcinoma, known or suspected pregnancy, age >35 years and smoking ≥15 cigarettes/day.
Data Pending Review
Data Pending Review
No significant food interactions. Grapefruit may slightly alter estrogen metabolism but clinically not significant. Maintain consistent dietary habits if constipating.
No specific food interactions are reported for Tri-Legest 21. Grapefruit juice may increase ethinyl estradiol levels but is not considered clinically significant. Patients should avoid St. John's Wort (herbal supplement) as it may reduce contraceptive efficacy. No dietary restrictions are required; however, a balanced diet is recommended to manage potential nausea. Caffeine metabolism may be affected by oral contraceptives; monitor for increased caffeine effects if consumed in excess.
FDA Category X. Use contraindicated in pregnancy due to risk of congenital anomalies, particularly cardiovascular and limb defects, from exposure during first trimester. Second and third trimester exposure associated with potential for fetal harm, including androgenization of female fetuses and liver adenoma. Discontinue promptly if pregnancy occurs.
First trimester: Epidemiologic studies have not found an increased risk of neural tube defects or other major malformations with combined oral contraceptives. Second and third trimesters: Fetal exposure to estrogen and progestin may cause masculinization of female genitalia if ethinyl estradiol/levonorgestrel is used inadvertently. No known association with congenital heart defects or other structural anomalies.
Enters breast milk in small amounts (M/P ratio not established). May reduce milk production and quality. Use caution in nursing mothers, especially during early postpartum period. Consider alternative contraception until weaning.
Small amounts of ethinyl estradiol and levonorgestrel pass into breast milk. The milk-to-plasma (M/P) ratio for levonorgestrel is approximately 0.37. Combined oral contraceptives may reduce milk production and alter milk composition. Use is generally not recommended during breastfeeding, especially in the immediate postpartum period until milk supply is established. Progestin-only contraceptives are preferred.
Contraindicated in pregnancy; no dose adjustments recommended as use is precluded. If inadvertently used, discontinue immediately.
TRI-LEGEST 21 is contraindicated during pregnancy. No dose adjustment is applicable; the drug should be discontinued immediately if pregnancy occurs. Pharmacokinetic changes in pregnancy (increased clearance of ethinyl estradiol and levonorgestrel) do not warrant dose adjustment because use is contraindicated.
Category C
Category C
Tri-Lo Sprintec is a triphasic oral contraceptive with ethinyl estradiol and norgestimate. Monitor for thromboembolic events, especially in smokers over 35. Advise use of backup contraception if vomiting/diarrhea occurs. CYP3A4 inducers may reduce efficacy.
Tri-Legest 21 is a triphasic oral contraceptive containing ethinyl estradiol and norethindrone. For first-time users, start on the first Sunday after menstrual period onset; if starting on any other day, use backup contraception for 7 days. Missed pill management: if one pill is missed, take it as soon as remembered and next pill at usual time; if two consecutive pills are missed in week 1 or 2, take two pills daily for two days and use backup contraception for 7 days; if two pills missed in week 3 or three pills missed anytime, discard remaining pills, start a new pack on the same day (if Sunday starter, continue daily) and use backup contraception for 7 days. Monitor for breakthrough bleeding, especially in first 3 cycles; if persistent, rule out pregnancy or consider alternative formulation. Check for contraindications including migraine with aura, hypertension (BP >160/100), smokers over 35, history of thromboembolic events, and liver disease. Evaluate for drug interactions with rifampin, certain anticonvulsants (phenytoin, carbamazepine, topiramate), and St. John's Wort which may decrease efficacy.
Take one tablet daily at the same time; missed doses increase pregnancy risk.Use backup contraception for 7 days after missing 2 or more pills.Report symptoms of blood clots: leg pain/swelling, chest pain, sudden shortness of breath.Avoid smoking while on this medication, especially if over 35.May cause irregular bleeding initially; contact provider if persistent.
Take one pill daily at the same time each day for 21 days, then no pills for 7 days; withdrawal bleeding usually occurs during the pill-free week.If you miss a pill, refer to the package insert or call your healthcare provider; general rule: take missed pill as soon as remembered and continue regular schedule; use backup contraception (condoms) if needed.Common side effects include nausea, breast tenderness, headache, and breakthrough spotting, especially in first few months; these often improve with time.This medication does not protect against sexually transmitted infections (STIs); use condoms for STI prevention.Do not smoke while taking this medication; smoking increases risk of serious cardiovascular side effects, especially if you are over 35.Tell your healthcare provider if you have unexplained leg pain or swelling, sudden severe headache, vision changes, or chest pain; these could be signs of a blood clot.Inform all healthcare providers (including dentists) that you are taking an oral contraceptive.If you experience severe upper abdominal pain or yellowing of skin/eyes, stop medication and contact your healthcare provider immediately.